Dexcom Inc Stock Price, News & Analysis

Synchron, a brain-computer interface (BCI) company, has strengthened its executive team with two significant appointments. Andy Rasdal, former DexCom (NASDAQ: DXCM) CEO, joins as Chief of Staff while continuing his Board position, and Mark Brister takes the role of VP R&D.

Rasdal brings over 30 years of medical device industry experience, notably leading DexCom through FDA approval and IPO, and previously serving as President of Medtronic Vascular. Brister contributes 38 years of experience in medical device technologies, with over 450 patents and involvement in launching more than 100 products.

These appointments aim to advance Synchron's Stentrode® BCI through U.S. clinical trials and prepare for global market entry, potentially transforming treatment for millions with motor impairment.

Dexcom (NASDAQ:DXCM) reported strong Q2 2025 financial results with revenue growing 15% year-over-year to $1.157 billion. The company achieved GAAP operating income of $212.6 million, representing 18.4% of revenue. Dexcom also announced a CEO succession plan, with Jake Leach set to become CEO effective January 1, 2026, while current CEO Kevin Sayer will transition to executive chairman.

Key highlights include FDA clearance for the Dexcom G7 15 Day CGM System, launch of AI-based Smart Food Logging, and enhanced Stelo customer experience. The company raised its 2025 revenue guidance to $4.600-$4.625 billion (14-15% growth) while maintaining guidance for other metrics, including Non-GAAP Operating Margin of approximately 21%.

The company maintains a strong financial position with $2.93 billion in cash, cash equivalents, and marketable securities.

Dexcom (NASDAQ: DXCM) announced the expansion of coverage for its Dexcom G7 Continuous Glucose Monitoring (CGM) System under Ontario's Drug Benefit (ODB) program. The coverage now extends to eligible Ontarians managing diabetes with insulin, impacting a significant portion of the estimated 1.7 million people living with diabetes in Ontario.

The Dexcom G7, recognized as the most accurate CGM and the #1 preferred glucose sensor by Canadian endocrinologists, offers unique features including a predictive urgent low alert, waterproof sensor, 30-minute warm-up time, and direct Apple Watch functionality. The expanded coverage makes Dexcom G7 the most covered CGM on government-funded programs in Ontario, available through ODB, ADP, private insurance, and NIHB programs.

Dexcom (NASDAQ:DXCM), the global leader in glucose biosensing, has launched a groundbreaking AI-powered Smart Food Logging feature across its product portfolio. The feature is now available on both Stelo, the first FDA-cleared over-the-counter glucose biosensor, and Dexcom G7, making it the only prescription continuous glucose monitor in the U.S. with photo logging capability.

The innovative feature allows users to simply take a photo of their food in the app, where AI automatically identifies ingredients and populates meal descriptions. This launch is accompanied by several other technological enhancements, including Weekly Insights powered by GenAI, Oura integration for holistic biometric tracking, customizable target ranges in Dexcom G7, and a new Glucose Impact feature for better understanding of how various activities affect glucose levels.

Users can access these features by updating to the latest version of their respective apps on iOS and Android platforms.

Dexcom (NASDAQ:DXCM) has announced the fourth season of its groundbreaking Dexcom U NIL program, exclusively for college athletes with diabetes. The 2025 roster features 21 total athletes, including 13 new members and 8 returning participants from various colleges across the United States.

The company hosted its first-ever Dexcom U Signing Day Camp in Baltimore, featuring Baltimore Ravens tight end Mark Andrews and NFL legend Mike Golic Sr. The program, launched in 2022, has impacted over 40 college athletes across 38 schools and 19 sports. All participants use Dexcom's continuous glucose monitoring (CGM) technology to manage their diabetes while competing at the collegiate level.

DexCom (NASDAQ:DXCM) has scheduled its second quarter 2025 earnings release and conference call for July 30, 2025. The company will release its financial results after market close, followed by a management conference call at 4:30 p.m. Eastern Time to review the quarterly performance.

Investors can access the conference call by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using confirmation ID "9430114". A concurrent webcast will be available on the Dexcom investor relations website at investors.dexcom.com, where it will also be archived for future reference.

Dexcom (DXCM) released its 'State of Type 2 Report' ahead of the ADA Scientific Sessions, revealing significant healthcare professional support for Continuous Glucose Monitoring (CGM) in Type 2 diabetes management. The report shows 59% of U.S. HCPs believe better CGM access will be most effective for diabetes management in the next decade. Notably, 96% support CGM as standard care for multiple daily insulin injections, and 100% recommend CGM with GLP-1 medications. The company will present clinical data at ADA 2025 demonstrating CGM benefits, including reduced mortality risk for insulin users and improved self-management for non-insulin users. Dexcom Warrior Lance Bass will share his experience with Dexcom G7 technology at the conference. The report also highlights that 60% of HCPs believe additional funding for CGM coverage could increase adoption among Type 2 diabetes patients.

Dexcom (NASDAQ: DXCM), a leader in real-time continuous glucose biosensing, has promoted Jake Leach to the role of president while maintaining his position as chief operating officer. Leach, who has over 21 years of leadership experience at Dexcom, has been instrumental in developing the company's biosensing platforms since their first commercial system launch.

In his COO role, which he has held since 2022, Leach oversees product development, global operations, R&D, quality management, regulatory and medical affairs. His expanded role as president will include additional oversight of Dexcom's corporate development and strategy efforts. CEO Kevin Sayer expressed strong confidence in Leach's ability to build upon his track record of innovation and achievement in metabolic health.

DexCom (DXCM) reported strong Q1 2025 financial results with revenue growing 12% year-over-year to $1.036 billion. The company saw U.S. revenue growth of 15% and international revenue growth of 7%. GAAP operating income reached $133.7 million, representing 12.9% of revenue.

Key developments include broader coverage with 2 of 3 largest PBMs now covering Dexcom CGM for diabetes patients, Stelo's launch on Amazon, and FDA clearance for the Dexcom G7 15 Day System. The company announced a $750 million share repurchase program and updated its 2025 guidance, projecting revenue of $4.60 billion (14% growth) with Non-GAAP Operating Margin of approximately 21%.